Many countries either lack appropriate clinical practice guidelines for the diagnosis and treatment of HCC or the quality of their guidelines has never been evaluated. The main objective of our ...

Amezalpat received fast track designation from the FDA for the treatment of patients with hepatocellular carcinoma.

China: A recent study published in the Annals of Hepatology has emphasized the influence of age on hepatocellular carcinoma ...

Hepatobiliary cancers, which include biliary tract cancer (BTC) and hepatocellular carcinoma (HCC), are among the most lethal ...

Researchers assessed the prognostic significance of older age and comorbidity burden on overall survival in patients with hepatocellular carcinoma.

The FDA has granted fast track designation to amezalpat for the treatment of patients with hepatocellular carcinoma.

End-of-life (EOL) outcomes and healthcare utilization for patients with hepatocellular carcinoma (HCC) who received immune checkpoint inhibition (ICI). This is an ASCO Meeting Abstract from the 2025 ...

Unresectable canine hepatocellular carcinoma (HCC) has limited nonsurgical treatment options. Sorafenib is a targeted therapy for unresectable canine HCC. However, there are limited reports on the ...

Amezalpat has been granted FDA fast track designation as treatment for patients with hepatocellular carcinoma.

Oncolytic viruses (OVs) are viruses that infect and kill cancer cells while sparing healthy tissue, making them a promising therapeutic option in cancer ...

Overall, the mean score was 55% (ranging from 11% to 100%) indicating that the criteria of scope and purpose were met by most of the guidelines. Of the 32 guidelines, only 11 scored more than 60% ...